Biosimilar, biobetter, and next generation antibody characterisation by mass spectrometry
Alain Beck, Centre d'Immunologie Pierre Fabre (CIPF), St Julien-en-Genevois/F
Genomics and other omics technologies of mammalian host cells
Michael J. Betenbaugh, Johns Hopkins University, Baltimore/USA
Leptospira licerasiae - a novel bacterial contamination in biopharmaceutical manufacturing
Sven Deutschmann, Roche Diagnostics GmbH, Penzberg/D
In the aftermath of TNG1412: new preclinical approaches to assess mAb function
Ulrich Kalinke, Hannover Medical School / TWINCORE GmbH, Hanover/D
Mass spectrometry based proteomics in pre-clinical drug discovery
Bernhard Kuster, Technische Universität München, Freising/D
Considerations about physicochemical characterization of maytansinoid ADCs
Alex Lazar, ImmunoGen, Inc., Waltham/USA
Engineering of antibodies for successful development
Lars Linden, Bayer Healthcare, Wuppertal/D
High-performance glycoanalysis - combining MALDI-MS, CE-MS and xCGE-LIF
Erdmann Rapp, Max Planck Institute for Dynamics of Complex Technical Systems / glyXera GmbH, Magdeburg/D
Analytical characterization of antibody mixtures in process development and manufacturing
Jette Wagtberg Sen, Symphogen A/S, Lyngby/DK